Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells

Chen, Feng; Wang, Tianyou; Tang, Ruihong; Wang, Jianwen; Long, Hui; Gao, Xiao‐Ning; Tang, Suo-Qin

doi:10.1007/s00383-010-2703-5

Cited by 25 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies transferrin and insulin had successfully been attached to the activated HSA NP with Traut's reagent in order to react with the maleimide crosslinker NHS-PEG-MAL-5000 (Ulbrich et al, 2011). In the present study, folic acid was covalently linked to HSA NPs and NP uptake was studied in human neuroblastoma (UKF-NB-3) and rat glioblastoma (101/8) cells, representing two cell lines that can be targeted by the use of folic acid (Ciofani et al, 2008;Feng et al, 2010). Moreover, both cell lines are models for cancer diseases with a poor outcome.…”

Section: Introductionmentioning

confidence: 92%

Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells

Ulbrich

Michaelis

Rothweiler

et al. 2011

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 92%

Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells

Ulbrich

Michaelis

Rothweiler

et al. 2011

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…For instance, folate-conjugated SNALPs (2.5% PEG, 2.5% folate-PEG) targeting folate receptors on cancer cells can knock down 40% of targeted MYCN gene in vivo [104]. AA-modified MCNPs (11% PEG, 11% AA-PEG) have three times gene silencing efficiency compared with non-modified LCPs [105].…”

Section: Surface Targeting Ligands On Sirna Deliverymentioning

confidence: 99%

Effect of surface properties on liposomal siRNA delivery

2016

View full text Add to dashboard Cite

Liposomes are one of the most widely investigated carriers for siRNA delivery. The surface properties of liposomal carriers, including the surface charge, PEGylation, and ligand modification can significantly affect the gene silencing efficiency. Three barriers of systemic siRNA delivery (long blood circulation, efficient tumor penetration and efficient cellular uptake/endosomal escape) are analyzed on liposomal carriers with different surface charges, PEGylations and ligand modifications. Cationic formulations dominate siRNA delivery and neutral formulations also have good performance while anionic formulations are generally not proper for siRNA delivery. The PEG dilemma (prolonged blood circulation vs. reduced cellular uptake/endosomal escape) and the side effect of repeated PEGylated formulation (accelerated blood clearance) were discussed. Effects of ligand modification on cationic and neutral formulations were analyzed. Finally, we summarized the achievements in liposomal siRNA delivery, outlined existing problems and provided some future perspectives.

show abstract

“…showed that systemic administration of APRPG‐miR‐499 in mice bearing Colon 26 NL‐17 carcinoma significantly improved tumor blood flow, therefore, mice pre‐treated with APRPG‐miR‐499 exhibited enhanced tumor accumulation of DOX and, demonstrating superior anticancer effect of the combination therapy . Furthermore, the same strategy has been utilized by other groups to develop targeted cationic liposomes which proved remarkable in vitro and in vivo siRNA transfection efficiency; for example, FR‐targeted PCLs for MYCN siRNA delivery, and nucleolin‐targeted PCLs for anti‐BRAF siRNA delivery . Whitehead et al.…”

Section: Nanocarriersmentioning

confidence: 99%

Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment

Peng

Bariwal

Kumar

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Nanocarriers have the capability to deliver a variety of drugs to disease sites. Different biological barriers prevent the successful delivery of nanoformulations to target sites, thereby limiting effective therapeutic response. Although numerous efforts have been made to design novel nanocarriers by incorporating various functionalities to get better therapies, most strategies have failed to translate drug delivery systems to the clinic. Impediments such as the incapability to hold drugs stably in nanocarriers during circulation, non‐specific distribution, and inadequate delivery of therapeutic agents to target sites due to complex tumor microenvironment remain a challenge. Herein, different organic polymer and lipid‐based nanocarriers and their encouraging therapeutic effectiveness to treat cancer are discussed. Recent development in multifunctional and stimuli sensitive nanocarriers is also highlighted. Finally, the challenges and innovative strategies to overcome various obstacles and limitations for their successful translation into the clinic are discussed.

show abstract

Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells

Abstract: These results suggest that targeted delivery of MYCN siRNA by folate receptor-targeted lipid vesicles into LA-N-5 cells is efficacious and capable of suppressing MYCN mRNA expression both in vitro and in vivo.

Cited by 25 publications

References 25 publications

Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells

Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells

Effect of surface properties on liposomal siRNA delivery

Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment

Contact Info

Product

Resources

About